Hide metadata

dc.date.accessioned2020-05-27T19:26:07Z
dc.date.available2020-05-27T19:26:07Z
dc.date.created2020-01-29T12:58:10Z
dc.date.issued2020
dc.identifier.citationKamiński, Krzysztof Esguerra, Camila V. Gawel, Kinga Aurelia . N-Benzyl-(2,5-dioxopyrrolidin-1-yl)propanamide (AS-1) with Hybrid Structure as a Candidate for a Broad-Spectrum Antiepileptic Drug. Neurotherapeutics. 2019
dc.identifier.urihttp://hdl.handle.net/10852/76356
dc.description.abstractIn our recent studies, we identified compound N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide (AS-1) as a broad-spectrum hybrid anticonvulsant which showed potent protection across the most important animal acute seizure models such as the maximal electroshock (MES) test, the subcutaneous pentylenetetrazole (s.c. PTZ) test, and the 6-Hz (32 mA) test in mice. Therefore, AS-1 may be recognized as a candidate for new anticonvulsant effective in different types of human epilepsy with a favorable safety margin profile determined in the rotarod test in mice. In the aim of further pharmacological evaluation of AS-1, in the current study, we examined its activity in the 6-Hz (44 mA) test, which is known as the model of drug-resistant epilepsy. Furthermore, we determined also the antiseizure activity in the kindling model of epilepsy induced by repeated injection of pentylenetetrazole (PTZ) in mice. As a result, AS-1 revealed relatively potent protection in the 6-Hz (44 mA) test, as well as delayed the progression of kindling induced by repeated injection of PTZ in mice at doses of 15 mg/kg, 30 mg/kg, and 60 mg/kg. Importantly, the isobolographic analysis showed that a combination of AS-1 and valproic acid (VPA) at the fixed ratio of 1:1 displayed a supra-additive (synergistic) interaction against PTZ-induced seizures in mice. Thus, AS-1 may be potentially used in an add-on therapy with VPA. Moreover, incubation of zebrafish larvae with AS-1 substantially decreased the number, cumulative but not the mean duration of epileptiform-like events in electroencephalographic assay. Finally, the in vitro ADME-Tox studies revealed that AS-1 is characterized by a very good permeability in the parallel artificial membrane permeability assay test, excellent metabolic stability on human liver microsomes (HLMs), no significant influence on CYP3A4/CYP2D6 activity, and moderate inhibition of CYP2C9 in a concentration of 10 μM, as well as no hepatotoxic properties in HepG2 cells (concentration of 10 μM).en_US
dc.languageEN
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleN-Benzyl-(2,5-dioxopyrrolidin-1-yl)propanamide (AS-1) with Hybrid Structure as a Candidate for a Broad-Spectrum Antiepileptic Drugen_US
dc.typeJournal articleen_US
dc.creator.authorKamiński, Krzysztof
dc.creator.authorEsguerra, Camila V.
dc.creator.authorGawel, Kinga Aurelia
cristin.unitcode185,57,0,0
cristin.unitnameNorsk Senter for Molekylærmedisin
cristin.ispublishedtrue
cristin.fulltextoriginal
dc.identifier.cristin1785216
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Neurotherapeutics&rft.volume=&rft.spage=&rft.date=2019
dc.identifier.jtitleNeurotherapeutics
dc.identifier.volume17
dc.identifier.issue1
dc.identifier.startpage309
dc.identifier.endpage328
dc.identifier.pagecount20
dc.identifier.doihttps://doi.org/10.1007/s13311-019-00773-w
dc.identifier.urnURN:NBN:no-79424
dc.type.documentTidsskriftartikkelen_US
dc.type.peerreviewedPeer reviewed
dc.source.issn1933-7213
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/76356/1/10.1007_s13311-019-00773-w.pdf
dc.type.versionPublishedVersion
dc.relation.projectNFR/187615


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International